Detailed price information for Greenfire Resources Ltd. (GFR-T) from The Globe and Mail including charting and trades.

Discover why Greenfire Resources offers long-term value despite dilution fears—robust Q3 results, growth plans, and ...

The current kidney transplant waitlisting criterion is based on a single measurement of kidney function (estimated glomerular ...

Finerenone shows significant benefits in patients with kidney disease and type 1 diabetes, which could lead to the first ...

Greenfire Resources (NYSE:GFR) posted a dramatic turnaround in profitability, with net profit margins rising to 19.1% from just 5.1% a year ago and EPS surging 252.7% over the past year, a striking ...

The findings of this study support the routine use of sodium-glucose cotransporter 2 (SGLT2) inhibitors to improve kidney outcomes ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy ...

In late-breaking presentations at the American Society of Nephrology Kidney Week meeting and simultaneously published in two ...

NEW ORLEANS – A single injection of a gene-edited protein was deemed productive and safe in patients with dyslipidemia that ...

The first meta-analysis analyzed 70,361 participants from 10 randomized trials, and found those allocated to receive an SGLT2 ...

New research reveals that contrary toconventional belief, primary glomerular diseases are not necessarily benign for children ...

In the Chronic Kidney Disease Prognosis Consortium, 11% of outpatient participants and 35% of hospitalized patients had a cystatin C–based estimated glomerular filtration rate (eGFRcys) that was at ...